Radiopharmaceuticals Explained What Doctors Wish Patients Knew
Isotope Innovations >> Health>> Radiopharmaceuticals Explained What Doctors Wish Patients Knew
Radiopharmaceuticals Explained What Doctors Wish Patients Knew
Radiopharmaceuticals are medicinal products that contain a radioactive atom and are used to diagnose disease or deliver radiation to a targeted area. Doctors often wish patients knew that these medicines are not all the same: some create images that help find or monitor disease, while others are designed to treat it. Their benefits and risks depend on the specific drug, the condition being treated, and the patient’s circumstances. Understanding how they work, what to expect, and how to follow safety instructions can make a radiopharmaceutical procedure easier to navigate.
How radiopharmaceuticals work: diagnosis and treatment
The International Atomic Energy Agency describes radiopharmaceuticals as medicinal formulations containing radionuclides that are used for diagnosis or therapy. A radionuclide is an unstable atom that releases energy as it decays. The medicine’s other components help direct or carry it toward particular tissues, although distribution also depends on the drug and the body’s biology.
The central distinction is purpose. Diagnostic radiopharmaceuticals emit radiation that scanners can detect, helping clinicians assess how organs function or where disease may be located. Therapeutic radiopharmaceuticals deliver radiation intended to damage selected cells. Some treatments are systemic: the medicine travels through the bloodstream and targets cells with particular biological features. This is sometimes called targeted radionuclide therapy.
Diagnostic radiopharmaceuticals and medical imaging
In positron emission tomography (PET), a radiopharmaceutical emits positrons that ultimately produce signals detected by the scanner. In single-photon emission computed tomography (SPECT), the scanner detects gamma rays emitted by the radiopharmaceutical. These are functional imaging methods: they can reveal biological activity, such as glucose use or blood flow, in addition to showing anatomy.
For example, the U.S. Food and Drug Administration (FDA) lists fluorodeoxyglucose F 18, commonly called FDG, among PET drugs used in clinical imaging. FDG behaves in ways that allow clinicians to examine glucose metabolism. Increased uptake is not, by itself, proof of cancer: infection and other causes can also affect results. Imaging findings must be interpreted alongside the patient’s history, other tests, and the specific question being investigated.
Therapeutic radiopharmaceuticals and targeted treatment
Therapeutic radiopharmaceuticals use radiation to injure or destroy cells. Some attach to a target expressed by certain tumors; others concentrate in specific organs or tissues. The FDA-approved treatment lutetium Lu 177 dotatate, for example, is used for certain somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. The FDA-approved lutetium Lu 177 vipivotide tetraxetan is used for selected adults with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.
These examples do not mean every patient with the same cancer is eligible. Doctors consider whether the relevant target is present, the extent of disease, prior treatment, kidney and bone-marrow function, and the medicine’s approved indication. The National Cancer Institute explains that radiopharmaceutical therapy is one form of treatment that can deliver radiation to cancer cells while limiting exposure to surrounding tissues, but it cannot eliminate all risk to healthy cells.
Radiopharmaceutical benefits and risks: what patients should weigh
Radiopharmaceuticals can provide information or treatment that conventional anatomical imaging or medicines may not offer. Their use is nevertheless a clinical decision, not a guarantee of a diagnosis or cure. The expected benefit should be considered against possible side effects, radiation exposure, alternatives, and the consequences of not having the procedure.
Radiation dose depends on the specific procedure
There is no single radiation dose for “a nuclear medicine scan.” Dose varies with the radiopharmaceutical, the amount administered, the patient’s size and physiology, and whether additional imaging such as CT is performed. The International Commission on Radiological Protection (ICRP) emphasizes that medical exposure should be justified by expected benefit and optimized to keep exposure appropriate for the task. A diagnostic scan’s radiation exposure is different from therapeutic administration, where radiation is deliberately used to treat disease.
Patients can ask what the test is expected to answer, whether a non-radiation alternative is suitable, and whether earlier imaging can prevent unnecessary repetition. The FDA advises patients to discuss the benefits and risks of imaging procedures that use radioactive materials with their health-care team. Clinicians should use the lowest activity that still achieves the intended medical purpose, consistent with the procedure and patient.
Side effects vary between diagnostic and therapeutic drugs
Many diagnostic examinations involve a small administered amount and cause no immediate symptoms, though individual reactions and procedure-specific effects are possible. Therapeutic agents can cause more substantial effects because they are intended to deliver a cell-damaging dose. Depending on the drug, possible effects include fatigue, nausea, changes in blood counts, or effects on organs that take up or clear the medicine. The exact risks should be discussed using the product’s current prescribing information and the patient’s clinical situation.
For instance, FDA prescribing information for lutetium Lu 177 dotatate includes warnings about myelosuppression and kidney toxicity, among other risks. That information applies to that medicine and its indicated use; it should not be treated as a universal side-effect list for every radiopharmaceutical. Ask the treatment team which symptoms require an urgent call and which are expected to resolve.
Pregnancy, breastfeeding, and kidney function matter
Tell the care team if you are pregnant, might be pregnant, or are breastfeeding before receiving a radiopharmaceutical. Some procedures may need to be postponed, replaced, or managed with special instructions. Breastfeeding interruption recommendations differ by drug, so patients should obtain instructions for the exact radiopharmaceutical rather than relying on a general rule.
Kidney function can also matter because some radiopharmaceuticals or their breakdown products leave the body through urine. Other medicines may require checks of blood counts, liver function, or other measures before treatment. Share a complete medication list, including supplements, and tell the team about allergies, prior reactions, and relevant health conditions.
Preparing for a radiopharmaceutical procedure: practical expectations
Preparation is specific to the test or treatment. Fasting, medication changes, hydration, blood tests, or arrival timing may be required for one procedure and unnecessary for another. Follow the instructions from the nuclear medicine department; do not stop prescribed medicines unless the clinician tells you to.
Before the appointment
Confirm the name and purpose of the procedure, the preparation steps, and whether you should bring prior scans or laboratory results. For a PET examination using FDG, for example, the facility may give instructions about food, exercise, and blood glucose because these can affect image quality. Requirements vary by protocol and patient, so the imaging center’s directions take precedence over generic advice.
Tell staff about pregnancy possibility, breastfeeding, diabetes, kidney problems, and any recent nuclear medicine tests or treatments. If you have diabetes or need assistance with mobility or communication, ask in advance how the appointment will be adapted.
During and after administration
The radiopharmaceutical may be given by injection, swallowed, inhaled, or administered by another route, depending on the product. Imaging may begin immediately or after a waiting period that allows the medicine to distribute. The scan itself is often painless, though remaining still or lying in one position may be uncomfortable. Treatment visits can involve monitoring and follow-up tests beyond the administration itself.
Afterward, some diagnostic agents leave the body relatively quickly; others remain detectable longer. Drinking fluids or urinating frequently may be advised for certain procedures, but patients should follow the instructions given for their particular drug. Therapeutic treatments may require scheduled blood tests and follow-up appointments to assess response and monitor side effects.
Radiation safety after treatment: simple, individualized precautions
After some therapeutic administrations, a small amount of radioactivity may remain in the body temporarily. The treatment team will explain whether precautions are needed around other people, especially children and pregnant people, and for how long. Instructions depend on the radionuclide, administered activity, physical clearance, and local radiation-safety guidance; there is no universal restriction that applies to every patient.
Patients should ask for written instructions covering contact, travel, bathroom hygiene, laundry, and what to do if they need emergency care. Do not improvise restrictions or stop necessary treatment based on general online advice. The International Atomic Energy Agency’s patient-safety guidance emphasizes clear communication and appropriate radiation protection while maintaining the benefits of medically justified procedures.
Questions doctors wish patients would ask
- What question will this radiopharmaceutical procedure answer, and how could the result change my care?
- Is this test diagnostic or therapeutic, and what exact drug will I receive?
- What are the likely benefits, important risks, and reasonable alternatives for me?
- Do my pregnancy status, breastfeeding, kidney function, other conditions, or medicines change the plan?
- What preparation should I follow, and whom should I contact if I cannot follow it?
- Will I need radiation-safety precautions afterward, and can I have those instructions in writing?
- When and how will I receive the results, and what follow-up is planned?
Conclusion: informed decisions make radiopharmaceutical care safer
Radiopharmaceuticals are medicines that use radioactive atoms for imaging or treatment. Diagnostic agents help clinicians examine biological function, while therapeutic agents deliver radiation to selected tissues or targets. As the FDA, International Atomic Energy Agency, National Cancer Institute, and ICRP materials make clear, the benefits, doses, preparation, side effects, and safety instructions depend on the exact product and clinical purpose.
Before a procedure, ask what it is meant to achieve, what alternatives exist, and what you should do before and afterward. Share relevant health information and follow the nuclear medicine team’s instructions. For further reading, consult the FDA’s patient information and prescribing information for the specific drug, the National Cancer Institute’s radiopharmaceutical therapy resources, and your treating facility’s guidance.
Sources: International Atomic Energy Agency, Radiopharmaceuticals, https://www.iaea.org/topics/radiopharmaceuticals; U.S. Food and Drug Administration, PET Drugs—Current Good Manufacturing Practice, https://www.fda.gov/drugs/human-drug-compounding/pet-drugs-current-good-manufacturing-practice-cgmp; U.S. Food and Drug Administration, Lutathera (lutetium Lu 177 dotatate) prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208700s000lbl.pdf; U.S. Food and Drug Administration, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) prescribing information, https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf; National Cancer Institute, Radiopharmaceutical Therapy, https://www.cancer.gov/about-cancer/treatment/types/radiation-therapy/radiopharmaceuticals-fact-sheet; International Commission on Radiological Protection, Radiological Protection in Medicine, https://www.icrp.org/publication.asp?id=ICRP%20Publication%20105.
Related Post
- February 5, 2026
- by Wesley
- 0
- 12:00 am
Confused About Healthcare Technology Here Is What It Really Includes and Why It Matters
Healthcare Technology: Definition and Scope Healthcare technology encompasses a wide array of tools, systems, and…
- August 4, 2026
- by Wesley
- 0
- 12:00 am
